On the Action Mechanism of Some Fibrinolysis Inhibitors

L Donner; J Housková

doi:10.1055/s-0038-1655053

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 1967; 18(03/04): 439-446
DOI: 10.1055/s-0038-1655053

Originalarbeiten — Original Articles — Travaux Originaux

Schattauer GmbH

On the Action Mechanism of Some Fibrinolysis Inhibitors

L Donner

¹Second Medical Department Charles University, Prague, Czechoslovakia (Head: Professor F. Herles, M. D., D. Sc.)

,

J Housková

¹Second Medical Department Charles University, Prague, Czechoslovakia (Head: Professor F. Herles, M. D., D. Sc.)

› Institutsangaben

Abstract

Summary

1. Both p-aminomethylcyclohexanecarboxylic acid (AMCA) and p-aminomethylbenzoic acid (PAMBA) exhibit a significant inhibiting activity on the fibrinolysis. The inhibition conldbe observed already at concentrations as low as 10^-4 M. The inhibition was higher in a system activated by urokinase than in a system activated by streptokinase. By comparing the same concentrations the greatest inhibitory activity was observed in AMCA, a lesser one in PAMBA, and the least one in EACA.

2. AMCA exhibited mostly an antiactivator effect; the inhibition of pi asm in was very weak.

3. Intravenous injections of either AMCA, in recommended therapeutic doses of 15-20 mg/kg body weight, or PAMBA, in recommended therapeutic doses of 1.5 mg/kg body weight, exhibited an inhibitive effect on the fibrinolysis in vivo. Their effects set on, on the average, inside 30-60 min, and lasted 2-6 hrs. Great individual variations were found. AMCA had the highest inhibitory effect.

4. AMCA inhibits not only the blood activator but also the tissue activator. AMCA possesses, apart from the antifibrinolytic and antifibrinogenolytic activity, also a significant antitryptic activity.

Volltext

Referenzen

References
1 Andersson L, Nilson I. M. Fibrinolytic Activity in Man During Surgery. Thrombos. Diathes. haemorrh. (Stuttg). 07: 391 1962;
2 Andersson L, Nilson I. M, Niléhn J. E, Hedner E, Grandstrand B, Melander B. Experimental and Clinical Studies on AMCA, the Antifibrinolytically Active Isomer of p-Aminomethyl Cyclohexane Carboxylic Acid. Scand. H. Haem. 02: 230 1965;
3 Astrup T. N, Alkjaersig N. Classification of Proteolytic Enzymes by Means of their Inhibitors. Nature. 169: 314 1952;
4 Astrujp T, Albrechtsen V. K. Estimation of the Plasminogen Activator and the Trypsin Inhibitor in Animal and Human Tissues. Scand. J. clin. Inv. 09: 233 1957;
5 Astrup T, Alkjaersig N. Estimation of Proteolytic Enzymes by Means of their Fibrinolytic Activity. Arch. Bioch. 37: 99 1952;
6 Beck E, Schmutzler R, Duckert F. Inhibition of Fibrinolysis and Fibrinogenolysis in Man. Comparison of e-Aminocaproic Acid and Kallikrein Inhibitor. Thrombos. Diathes. haemorrh. (Stuttg). 10: 106 1963;
7 Čepelâk V, Horâkovâ Z, Padr Z. Protease Inhibitor from Ground and Skin. Nature (Lond). 198: 295 1963;
8 Donner L, Krcilek A. Zmëny fibrinolysy a hemokoagulace pri trombolytické lécbë. Cas. Lék. ces. 104: 641 1965;
9 Dubber A. H, McNicol G. P, Douglas A. S. Cyklohexane Carboxylic Acid (AMCA) a New Synthetic fibrinolytic Inhibitor. Brit. J. Haem. 11: 237 1965;
10 Fischer M. Zur Wirkung eines neuen synthetischen Inhibitors des fibrinolytischen Systems. AB Kabi Bericht. No. 377, 1965
11 Fischer M. Vergleichende Untersuchungen der Fibrinolyseninhibitoren AMCA, e-ACA und PAMBA. Wien. Z. inn. Med. 47: 143 1966;
12 Forell M. M, Dobovicnik W. Untersuchungen über die Hemmfähigkeit des Blutes gegenüber Trypsin und deren Beeinflussung durch die intravenöse Verabreichung des Kallikrein -und Trypsin-Drüseninaktivator. Blut. 07: 136 1961;
13 Hartert H. Die Thrombelastographie. Z. exp. Med. 117: 189 1951;
14 Introzzi P. Die Inhibitoren der Fibrinolyse. 8. Cong. Eur. Soc. Hemat. 1961; 450.
15 Koutský J, Hladovec J, Padovec J, Mansfeld W. Über die antifibrinolytische Wirkung des aus dem Pankreas sublingual applizierten Inhibitors. Gynek. 148: 412 1959;
16 Kraut N, Frey E. K, Werle E. Über die Inaktivierung des Kallikreins. Z. physiol. Chem. 192: 1 1930;
17 Lohmann K, Markwardt F, Landmann H. Über neue Hemmstoffe der Fibrinolyse. Naturwissenschaften. 50: 502 1963;
18 Markwardt F, Klöcking H. P, Landsmann H. Vergleichende Untersuchungen über Antifibrinolytika. Thrombos. Diathes. haemorrh. (Stuttg). 15: 562 1966;
19 Meiander B, Gliniecki G, Grandstrand B, Hansfoff G. The Antifibrinolytically Active Isomer of AMCHA. Abstracts G 68 Xth Congress of the International Society of Haematology..
20 Nilsson I. M, Björkman S. E, Andersson L. Clinical Experiences with e-Aminocaproic Acid as an Antifibrinolytic Agent. Acta med. scand. 170: 487 1961;
21 Okamoto S, Okamoto U. AMCHA. A New Potent Inhibitor of the Fibrinolysis. Keio J. Med. 11: 105 1962;
22 Schmutzler R, Fürstenberg H. Fibrinolyse und Blutverlust nach Prostata Operationen und deren Beeinflußbarkeit durch Antifibrinolytica. Dtsch. med. Wschr. 91: 297 1966;
23 Schmutzler R, Beck E. Die Wirkung von e-Aminokapronsäure und Trasylol auf die Fibrinolyse. Schweiz, med. Wschr. 92: 1368 1962;
24 Soulier J. P, Prou-Wartelle O, Darmout J. Etude de divers inhibitors d’enzymes protéolyti- ques sur la coagulation et la fibrinolyse. Rev. Hémat. 15: 431 1960;
25 Vogel G. Klinische Erfahrungen mit p-Aminomethylbenzolsäure. Z. inn. Med. 21: 57 1966;
26 Weiss M, Yver J, Samama M, Dubort G. h. Effects dissociés d’un nouvel antifibrinolytique injecté “in vivo” sur les epreuves “in vitro” de fibrinolyse. Prese méd. 71: 1879 1963;